Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Esteve Quimica.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Esteve Quimica
Spain_new Flag
Country
Country
Spain
Address
Address
Passeig de la Zona Franca, 109, 4º Planta, 08038 Barcelona
Telephone
Telephone
+34 93 446 60 00

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.


Lead Product(s): Etilevodopa

Therapeutic Area: Neurology Product Name: Inbrija

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Acorda Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 07, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.


Lead Product(s): Etilevodopa

Therapeutic Area: Neurology Product Name: Inbrija

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Acorda Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 16, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, ESTEVE will have the exclusive distribution rights to INBRIJA in Germany and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Germany by mid-2022.


Lead Product(s): Etilevodopa

Therapeutic Area: Neurology Product Name: Inbrija

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Acorda Therapeutics

Deal Size: Undisclosed Upfront Cash: $5.6 million

Deal Type: Agreement November 09, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the supply agreement, ACORDA will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.


Lead Product(s): Etilevodopa

Therapeutic Area: Neurology Product Name: Inbrija

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Acorda Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 22, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.


Lead Product(s): Celecoxib,Tramadol Hydrochloride

Therapeutic Area: Neurology Product Name: E-58425

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Kowa Pharmaceuticals America

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 03, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY